Merkel Cell Carcinoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Merkel cell carcinoma (MCC) is an aggressive primary cutaneous neuroendocrine carcinoma arising from Merkel mechanoreceptor cells in the basal layer of the epidermis. It is a rare but highly lethal skin cancer, with approximately 2,500 new cases diagnosed annually in the United States, and incidence has more than doubled over the past two decades due to an aging and increasingly immunosuppressed population. Median age at diagnosis is 75 years, and MCC is approximately three times more common in men than women. Merkel cell polyomavirus (MCPyV) drives approximately 80% of cases through clonal viral integration and T-antigen-mediated oncogenesis. Ultraviolet radiation-induced high mutational burden drives the remaining 20% of virus-negative tumors. MCC has a substantially higher disease-specific mortality than melanoma — approximately 30% of patients die of this disease — reflecting its rapid growth, tendency for early locoregional and distant spread, and predilection for immunosuppressed hosts.

MCPyV infection is the dominant causative factor in approximately 80% of MCC cases. Viral integration into the tumor cell genome with consequent expression of oncogenic small T and large T antigens drives uncontrolled proliferation. The virus is ubiquitous in the human population but causes carcinoma only in susceptible hosts, particularly those with impaired T-cell-mediated immunity. UV radiation causes virus-negative MCC through an extremely high somatic mutation burden, with signatures resembling cutaneous squamous cell carcinoma. Established risk factors include advanced age (median 75 years), immunosuppression from HIV infection, solid organ transplantation (10-fold elevated risk), B-cell malignancies such as CLL, hematologic malignancies, and therapeutic immunosuppressive agents. Fair skin phototype, chronic sun exposure, and prior skin cancers are additional risk factors. Arsenic exposure is a rare occupational risk.

MCC characteristically presents as a rapidly enlarging (over weeks to months), painless, firm, skin-colored to red-violaceous or bluish dome-shaped nodule on sun-exposed skin surfaces. The head and neck region accounts for approximately 50% of primary sites, followed by the extremities. The overlying skin may appear shiny with surface telangiectasia. Satellite lesions and in-transit metastases representing dermal lymphatic tumor spread occur as cutaneous spread progresses. Regional inguinal or cervical lymph node enlargement is present in approximately 35% of patients at the time of diagnosis. Distant metastases (most commonly to the liver, bone, brain, and lung) are identified in 8-10% at initial presentation. The AEIOU mnemonic (Asymptomatic, Expanding rapidly, Immunosuppressed, Older than 50 years, UV-exposed site) encodes the characteristic clinical features and aids timely recognition by non-specialists.

Excisional or incisional skin biopsy with comprehensive immunohistochemistry is required for diagnosis. The characteristic IHC profile: CK20 (paranuclear dot-like staining pattern), synaptophysin, chromogranin A, and CD56 positive; TTF-1 negative — this last marker is critical for distinguishing MCC from cutaneous metastases of small cell lung cancer, which has an identical morphological appearance. MCPyV large T-antigen IHC and quantitative serum MCPyV antibody titers establish viral status, with prognostic and monitoring implications. Sentinel lymph node biopsy (SLNB) is recommended for all clinically node-negative patients because microscopic nodal involvement significantly upstages prognosis and guides adjuvant therapy. PET/CT or CT of the chest, abdomen, and pelvis is performed for systemic staging. AJCC 8th edition TNM staging is applied.

Localized MCC is managed with wide local excision achieving 1-2 cm surgical margins combined with sentinel lymph node biopsy. Adjuvant radiation therapy at 50-56 Gy to the primary site and involved regional nodal basin is standard practice for all stages to reduce local and regional recurrence rates, which are otherwise high. For patients with nodal involvement, completion lymph node dissection or definitive nodal irradiation is performed. For metastatic, unresectable, or recurrent MCC, immune checkpoint inhibitors have transformed outcomes: pembrolizumab (FDA-approved based on KEYNOTE-017 trial) and avelumab (FDA-approved based on JAVELIN Merkel 200 trial) each achieve durable objective response rates of 30-40% with superior long-term outcomes compared to historical platinum-etoposide chemotherapy. Carboplatin plus etoposide remains an option for patients with rapidly progressing visceral disease requiring immediate cytoreduction who cannot wait for immunotherapy response. Maintenance anti-PD-1 therapy in the adjuvant setting is under investigation.

Daily use of broad-spectrum sunscreen (SPF 30 or higher) and UV-protective clothing reduces cumulative UV exposure and lowers the risk of virus-negative MCC arising through UV mutagenesis. Immunosuppressed patients — including solid organ transplant recipients and CLL patients — should undergo total-body skin examinations by a dermatologist every 6-12 months, as their MCC risk is substantially elevated. Reduction of immunosuppression intensity should be carefully considered in transplant recipients who develop MCC, in discussion with the transplant team. HIV treatment with effective antiretroviral therapy reduces immunosuppression-related MCC risk. No MCPyV-specific vaccine currently exists. Any rapidly growing, unexplained skin nodule in an older adult — particularly on a sun-exposed site — should be biopsied promptly rather than observed.

Any unexplained skin nodule — especially on the face, scalp, or extremities — that has appeared recently and is growing visibly over days to weeks should prompt urgent dermatology evaluation. The painless nature of MCC frequently delays patient concern, but rapid growth is the key warning feature. Immunosuppressed individuals, transplant recipients, patients on chronic immunosuppressive therapy, and older adults with a history of extensive sun exposure or prior skin cancers face the highest risk and should maintain regular skin examinations. A new palpable lump in the neck, groin, or axilla accompanying a skin lesion may indicate nodal spread and requires same-week assessment. Patients already diagnosed with MCC need lifelong surveillance at a center with cutaneous oncology expertise, as relapses can occur more than 5 years after initial treatment.

Five-year disease-specific survival by AJCC stage: Stage I approximately 75%, Stage II 60%, Stage IIIA 55%, Stage IIIB 40-45%, Stage IV less than 20%. Pembrolizumab achieves a 5-year OS of approximately 26% in previously treated metastatic MCC. Immunosuppressed patients have significantly worse outcomes. SLNB-negative patients have 5-year survival exceeding 80%. The prognosis for Merkel Cell Carcinoma: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.